Cosopt Versus Xalatan

Sponsor

Pharmaceutical Research Network (Other)

Overall Status

Completed

CT.gov ID

NCT00273429

Collaborator

(none)

Locations

Duration (Months)

Study Details

Study Description

Brief Summary

To compare the 24-hour efficacy and safety, measured every three hours, of the dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each given once daily.

Condition or Disease	Intervention/Treatment	Phase
Open-Angle Glaucoma Ocular Hypertension	Drug: timolol maleate 0.5% Drug: dorzolamide/timolol maleate fixed combination Drug: latanoprost 0.005% Drug: placebo	Phase 4

Study Design

Study Type:

Interventional

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Double

Primary Purpose:

Treatment

Study Start Date :

Apr 1, 2005

Study Completion Date :

Dec 1, 2005

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

adults with primary open-angle, pigmentary, or exfoliation glaucoma, or ocular hypertenstion
intraocular pressure should be 22 to 30 mm Hg inclusive on timolol BID at the 08:00 H
ETDRS visual acuity must be 1.0 or better in both eyes